Opko Health

OPKO Health is a unique, fully-integrated biopharmaceutical and diagnostics company founded in 2007. Its core strategy combines the steady, high-volume revenue of its BioReference Laboratories diagnostics business with targeted therapeutic R&D in multispecific antibodies and long-acting delivery technologies. Key achievements include the global commercialization of NGENLA™ (somatrogon) with Pfizer and the marketing of RAYALDEE® for secondary hyperparathyroidism, while its research subsidiary, ModeX Therapeutics, advances a novel pipeline with partners like Merck and Regeneron. This hybrid model aims to de-risk drug development while pursuing transformative medicines for complex diseases.

Proprietary multispecific antibody platform capable of targeting up to six distinct pathways in a single molecule, and a nanoparticle vaccine platform designed to enhance antigen presentation and immunogenicity.

OPKO faces intense competition across all segments: in long-acting growth hormone from Novo Nordisk, in secondary hyperparathyroidism from Amgen and generics, and in multispecific antibodies from well-capitalized giants like Regeneron and Roche. Its diagnostics business competes directly with giants LabCorp and Quest Diagnostics on scale and cost.